Market Outlook:

Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease. Increasingly, drug developers are focusing on subsets of first-line CLL patients, such as elderly patients or those who harbor chromosome 17p deletions. The high unmet need for novel therapies with better efficacy and improved safety and tolerability profiles for the therapeutic management of first-line CLL presents notable commercial opportunity for drug developers.

Questions Answered:

  • What are the treatment drivers and goals for first-line CLL? How do current therapies, such as Johnson & Johnson/Janssen/AbbVie’s Imbruvica, perform on these metrics?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the prevailing areas of unmet need and opportunity in first-line CLL? Are late-phase emerging therapies targeting these areas?
  • What trade-offs are surveyed hematological oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in first-line CLL?

Production Description: Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Unmet Need - Detailed, Expanded Analysis (First-Line Chronic Lymphocytic Leukemia)

Author(s): Priti Girotra, M.Pharm., Ph.D

Priti Girotra, M.Pharm., Ph.D., is an analyst in the oncology team at Decision Resources Group and has authored insightful content on multiple indications including Non-Small-Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Cancer, Malignant Melanoma, and Multiple Myeloma. Prior to joining DRG, Dr. Girotra conducted her Ph.D. research on formulation optimization of nanoparticles containing triptan derivatives for effective brain targeting and therapeutic management of migraine, under a DST-INSPIRE Fellowship at G.J. University of Science & Technology, Hisar, India.


Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Epidemiology Dashboard

DRG Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report...

View Details